A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

Certolizumab Pegol

Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.

Trial Locations (6)

10, Los Angeles

4, Walnut Creek

8, Wheaton

1, Voorhees Township

6, Rochester

7, Franklin